251 related articles for article (PubMed ID: 38576019)
1. Systematic proteome-wide Mendelian randomization using the human plasma proteome to identify therapeutic targets for lung adenocarcinoma.
Zhang L; Xiong Y; Zhang J; Feng Y; Xu A
J Transl Med; 2024 Apr; 22(1):330. PubMed ID: 38576019
[TBL] [Abstract][Full Text] [Related]
2. Exploration of potential novel drug targets for diabetic retinopathy by plasma proteome screening.
Yuan W; Xu W; Xu X; Qu B; Zhao F
Sci Rep; 2024 May; 14(1):11726. PubMed ID: 38778174
[TBL] [Abstract][Full Text] [Related]
3. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases.
Zheng J; Haberland V; Baird D; Walker V; Haycock PC; Hurle MR; Gutteridge A; Erola P; Liu Y; Luo S; Robinson J; Richardson TG; Staley JR; Elsworth B; Burgess S; Sun BB; Danesh J; Runz H; Maranville JC; Martin HM; Yarmolinsky J; Laurin C; Holmes MV; Liu JZ; Estrada K; Santos R; McCarthy L; Waterworth D; Nelson MR; Smith GD; Butterworth AS; Hemani G; Scott RA; Gaunt TR
Nat Genet; 2020 Oct; 52(10):1122-1131. PubMed ID: 32895551
[TBL] [Abstract][Full Text] [Related]
4. ​Comprehensive mendelian randomization analysis of plasma proteomics to identify new therapeutic targets for the treatment of coronary heart disease and myocardial infarction.
Sun Z; Yun Z; Lin J; Sun X; Wang Q; Duan J; Li C; Zhang X; Xu S; Wang Z; Xiong X; Yao K
J Transl Med; 2024 Apr; 22(1):404. PubMed ID: 38689297
[TBL] [Abstract][Full Text] [Related]
5. Proteome-wide Mendelian randomization identifies potential therapeutic targets for nonalcoholic fatty liver diseases.
Li J; Ma X; Yin C
Sci Rep; 2024 May; 14(1):11814. PubMed ID: 38782984
[TBL] [Abstract][Full Text] [Related]
6. Mendelian randomization and genetic colocalization infer the effects of the multi-tissue proteome on 211 complex disease-related phenotypes.
Yang C; Fagan AM; Perrin RJ; Rhinn H; Harari O; Cruchaga C
Genome Med; 2022 Dec; 14(1):140. PubMed ID: 36510323
[TBL] [Abstract][Full Text] [Related]
7. Proteome-Wide Multicenter Mendelian Randomization Analysis to Identify Novel Therapeutic Targets for Lung Cancer.
Wang K; Yi H; Wang Y; Jin D; Zhang G; Mao Y
Arch Bronconeumol; 2024 May; ():. PubMed ID: 38824092
[TBL] [Abstract][Full Text] [Related]
8. Proteome-Wide Mendelian Randomization and Colocalization Analysis Identify Therapeutic Targets for Knee and Hip Osteoarthritis.
Zou M; Shao Z
Biomolecules; 2024 Mar; 14(3):. PubMed ID: 38540773
[TBL] [Abstract][Full Text] [Related]
9. Proteome-wide mendelian randomization study implicates therapeutic targets in common cancers.
Ren F; Jin Q; Liu T; Ren X; Zhan Y
J Transl Med; 2023 Sep; 21(1):646. PubMed ID: 37735436
[TBL] [Abstract][Full Text] [Related]
10. Integrating plasma proteomes with genome-wide association data for causal protein identification in multiple myeloma.
Wang Q; Shi Q; Wang Z; Lu J; Hou J
BMC Med; 2023 Sep; 21(1):377. PubMed ID: 37775746
[TBL] [Abstract][Full Text] [Related]
11. Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for lung cancer.
Song W; Li Y; Yao Y; Sun S; Guan X; Wang B
BMC Cancer; 2024 Jun; 24(1):680. PubMed ID: 38834983
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial related genome-wide Mendelian randomization identifies putatively causal genes for multiple cancer types.
Li Y; Sundquist K; Zhang N; Wang X; Sundquist J; Memon AA
EBioMedicine; 2023 Feb; 88():104432. PubMed ID: 36634566
[TBL] [Abstract][Full Text] [Related]
13. Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis.
Lin J; Zhou J; Xu Y
Brain; 2023 Aug; 146(8):3364-3372. PubMed ID: 36864689
[TBL] [Abstract][Full Text] [Related]
14. Mendelian randomization analysis identifies druggable genes and drugs repurposing for chronic obstructive pulmonary disease.
Wang Z; Li S; Cai G; Gao Y; Yang H; Li Y; Liang J; Zhang S; Hu J; Zheng J
Front Cell Infect Microbiol; 2024; 14():1386506. PubMed ID: 38660492
[TBL] [Abstract][Full Text] [Related]
15. Promising therapeutic targets for ischemic stroke identified from plasma and cerebrospinal fluid proteomes: a multicenter Mendelian randomization study.
Zou X; Wang L; Wang S; Zhang Y; Ma J; Chen L; Li Y; Yao TX; Zhou H; Wu L; Tang Q; Ma S; Zhang X; Tang R; Yi Y; Liu R; Zeng Y; Zhang L
Int J Surg; 2024 Feb; 110(2):766-776. PubMed ID: 38016292
[TBL] [Abstract][Full Text] [Related]
16. Potential therapeutic targets for membranous nephropathy: proteome-wide Mendelian randomization and colocalization analysis.
Su Z; Wan Q
Front Immunol; 2024; 15():1342912. PubMed ID: 38707900
[TBL] [Abstract][Full Text] [Related]
17. Causal associations between gastroesophageal reflux disease and lung cancer risk: A Mendelian randomization study.
Li L; Ren Q; Zheng Q; Bai Y; He S; Zhang Y; Ma H
Cancer Med; 2023 Mar; 12(6):7552-7559. PubMed ID: 36479899
[TBL] [Abstract][Full Text] [Related]
18. Potential drug targets for tumors identified through Mendelian randomization analysis.
Song N; Shi P; Cui K; Zeng L; Wang Z; Di W; Li J; Fan Y; Li Z; Zhang J; Su W; Wang H
Sci Rep; 2024 May; 14(1):11370. PubMed ID: 38762700
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Targets for Diabetic Kidney Disease: Proteome-Wide Mendelian Randomization and Colocalization Analyses.
Zhang W; Ma L; Zhou Q; Gu T; Zhang X; Xing H
Diabetes; 2024 Apr; 73(4):618-627. PubMed ID: 38211557
[TBL] [Abstract][Full Text] [Related]
20. Proteome-wide Mendelian randomization identifies therapeutic targets for ankylosing spondylitis.
Zhao W; Fang P; Lai C; Xu X; Wang Y; Liu H; Jiang H; Liu X; Liu J
Front Immunol; 2024; 15():1366736. PubMed ID: 38566994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
